Distinguished scientists present their results and perspectives on some of today’s most promising approaches to cellular therapies, involving regulatory T cells, NK cells, stem cells, neural cells, and CAR-expressing T cells.
Read on how Miltenyi Biotec revolutionized cell processing for both basic research and clinical application, and learn about a complete solution to uncover the full potential of xenograft technology.
The high-quality print version contains two fold-out pages highlighting the milestones that got us where we are today, and the breakthroughs that inspire us for tomorrow.
Get your electronic version of the MACS&more 16-1/2014 Anniversary Edition below. You can view it with a reader app that’s also compatible with both Android and Apple devices. Simply follow the link on your computer or mobile device.
► MACS&more Vol 16-1, 2014
Topics of the MACS&more Anniversary Edition include:
► Treg cells in solid organ transplantation
Cell manufacture for clinical studies
► NK cell transplantation
Consolidation therapy in children with acute myeloid leukemia – a pilot study
► Tackling autoimmune diseases
Resetting the immune system is associated with long-term remission
► Neural cells for tissue regeneration research
Differentiation from PSCs and subsequent isolation
► Chimeric antigen receptor–expressing T cells
Holding great promise for cancer immunotherapy
► The way to integrated cell processing
25 years of development and innovation at Miltenyi Biotec
► A leap forward in cancer research
Effective mouse cell depletion enables accurate, unbiased analysis of tumor xenografts
► Find additional MACS&more issues here.